This file photo, provided by Celltrion, shows Steqeyma, a biosimilar product for Stelara, an autoimmune disease treatment. (Image courtesy of Yonhap)
SEOUL, March 13 (Korea Bizwire) — Celltrion Inc., a major South Korean biopharmaceutical firm, said Thursday it has launched its biosimilar product for Stelara, an autoimmune disease treatment, in the United States.
Steqeyma, a treatment for plaque psoriasis, Crohn’s disease, active psoriatic arthritis and ulcerative colitis, is Celltrion’s seventh biosimilar product that has hit the U.S. market, the company said in a press release.
The U.S. Food and Drug Administration (FDA) approved the biosimilar drug in both intravenous and subcutaneous formulations in December, it said.
Celltrion has been making efforts to expand its presence in the U.S. biosimilar market.
In recent months, it has obtained FDA approval for the U.S. sale of several biosimilars, including Avtozma, an autoimmune disease biosimilar to Actemra, as well as Stoboclo and Osenvelt, biosimilar drugs to Prolia and Xgeva.
The global market for Stelara is estimated at US$10.36 billion, with the U.S. accounting for two-thirds of global sales.
Celltrion aims to commercialize 22 biosimilar products in global markets by 2030.
(Yonhap)
